美康生物品牌怎么样 申请店铺

我要投票 美康生物在医疗器械行业中的票数:1004 更新时间:2026-01-29
美康生物是哪个国家的品牌?「美康生物」是美康盛德旗舰店旗下著名品牌。该品牌发源于浙江省宁波市,由创始人邹 * 德在2003年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力美康生物品牌出海!将品牌入驻外推网,定制美康生物品牌推广信息,可以显著提高美康生物产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

美康生物怎么样

美康生物是一家专业从事医学诊断产品研发、生产、销售及服务的企业。公司创立于2003年,矗立于宁波,2015年在深交所创业板成功上市,股票代码300439。

美康生物主要产业为体外诊断试剂、仪器及独立第三方医学诊断服务。公司秉承以人为本、科技创新的宗旨来建立自己的特色,严格按照GMP标准组织生产。目前已取得140余项体外诊断试剂产品注册证书,是我国生化诊断试剂领域品种齐全的供应商之一;并取得9项诊断仪器产品注册证书,是行业内同时能够提供诊断试剂和诊断仪器的少数供应商之一。

公司打造以提供区域性医学检验服务为核心的第三方医学检验中心。拥有自主研发的区域LIS系统、现代化消毒中心、冷链物流系统、美康云平台等多项配套系统。大力助推分级诊疗的落地,加快各级医疗机构信息化改革的步伐,提升医院的管理水平、服务质量及综合竞争力。

美康生物成为医学检验集约化系统供应商,为客户提供实验室整体解决方案。公司将持续推出高科技含量产品,深入提供服务,为客户创造价值,为中国体外诊断事业的发展,为中国人民的健康做出更大贡献!


Meikang biology is a professional enterprise engaged in the research and development, production, sales and service of medical diagnosis products. Founded in 2003 and standing in Ningbo, the company was successfully listed on the growth enterprise market of Shenzhen Stock Exchange in 2015, with the stock code of 300439. Our main industries are in vitro diagnostic reagents, instruments and independent third-party medical diagnostic services. The company adheres to the tenet of people-oriented and scientific and technological innovation to establish its own characteristics and organize production in strict accordance with GMP standards. At present, it has obtained more than 140 in vitro diagnostic reagent product registration certificates, and is one of the suppliers with complete varieties in the field of biochemical diagnostic reagents in China. It has also obtained 9 registration certificates of diagnostic instrument products, which is one of the few suppliers in the industry that can provide diagnostic reagents and diagnostic instruments at the same time. The company has built a third-party medical testing center with the core of providing regional medical testing services. It has self-developed regional LIS system, modern disinfection center, cold chain logistics system, Meikang cloud platform and other supporting systems. Vigorously promote the implementation of hierarchical diagnosis and treatment, accelerate the pace of information-based reform of medical institutions at all levels, and improve the management level, service quality and comprehensive competitiveness of hospitals. Meikang biology has become a supplier of intensive medical testing system, providing customers with overall laboratory solutions. The company will continue to launch high-tech products, provide in-depth services, create value for customers, and make greater contributions to the development of China's in vitro diagnostic industry and the health of the Chinese people!

本文链接: https://brand.waitui.com/eed8e50ac.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

苹果据悉今年9月只上iPhone18 Pro系列和首款阔折叠Fold

市场消息称,苹果iPhone 18预计明年Q1推出,9月只上iPhone18 Pro系列和首款阔折叠iPhone Fold,基本都是万元机档位。苹果今年秋季发布的所有新款iPhone都配备12GB内存,涵盖iPhone 18 Pro、iPhone 18 Pro Max以及iPhone Fold(折叠屏 iPhone),与 iPhone 17 Pro系列所采用的12GB内存保持一致。(财联社)

2小时前

美股大型科技股盘前多数上涨,英特尔涨超5%

36氪获悉,美股大型科技股盘前多数上涨,截至发稿,英特尔涨超5%,英伟达涨超2%,谷歌涨0.44%,亚马逊涨0.22%,微软涨0.31%,特斯拉涨0.19%,Meta跌0.28%,苹果跌0.19%。

2小时前

热门中概股美股盘前普涨,哔哩哔哩涨超4%

36氪获悉,热门中概股美股盘前普涨,截至发稿,哔哩哔哩涨超4%,蔚来、理想汽车涨超3%,阿里巴巴、网易、小鹏汽车涨超2%,百度涨超1%,拼多多涨0.61%,京东涨0.54%。

2小时前

星巴克:第一季度美国同店销售额增长4% 高于市场预期

星巴克第一季度美国同店销售额增长4%,预估为增长1.88%。星巴克预计全年同店销售至少增长3%,市场预估增长2.83%;预计全年调整后每股收益2.15美元至2.40美元。(财联社)

2小时前

*ST铖昌:预计2025年净利润9500万元-1.24亿元,公司股票存在可能被终止上市的风险

36氪获悉,*ST铖昌公告,*ST铖昌预计2025年归属于上市公司股东的净利润为9500万元–12400万元,上年同期为亏损3111.79万元,同比扭亏为盈。公司股票因2024年度经审计净利润为负值且扣除后营业收入低于3亿元,自2025年4月24日起被实施退市风险警示。若公司2025年度出现《深圳证券交易所股票上市规则》第9.3.12条规定的相关情形,公司股票将面临被终止上市的风险。公司已披露股票可能被终止上市的风险提示公告,并计划更换会计师事务所以推进2025年度审计工作。

2小时前

本页详细列出关于美康生物的品牌信息,含品牌所属公司介绍,美康生物所处行业的品牌地位及优势。
咨询